VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 Reviewer: Stephen Fremes; Institution and Country Sunnybrook Health Sciences Centre -University of Toronto; Toronto; Ontario, Canada.
1.In terms of organization, the submission seems like 2 protocol submissions, which are similar but not identical. It is preferable if there is a single merged protocol. A: We thank the reviewer for his suggestion. A single merged protocol is now reported, and a SPIRIT checklist added to the submission. C: Second part was completely deleted. A SPIRIT Checklist is now added.
2.The study will be very important, but would be much more valuable if TF TAVR was also included. And as the landscape is changing so quickly, will be of greater importance by the time this project is completed. A: We thank for the appreciation and agree with the reviewer that the enrollment of TF TAVR would have been of greater interest. Unfortunately, some of the interventional cardiologists of the involved centers denied to participate in the registry and to provide data about their percutaneous TAVR practice (also in view of their enrollment in other studies, some RCTs). Therefore, the enrollment of only few percutaneous TAVR would have certainly biased -at least in our opinion -all the analyses about future comparisons between different techniques. Furthermore, surgical TAVR will be all included in the registry, therefore some conclusions about the long-term safety, efficacy, durability, and functional results (e.g. NYHA, QoF) achieved with transcatheter valves could certainly be reached (in light of the fact that surgical TAVR and percutaneous TAVR share the same "platforms" in terms of prosthetic materials, storage, deployment, etc). Furthermore, it has to be considered that "surgical" TAVR are still performed in a routine fashion in the enrolled Institutions. For all these reasons EAVR-Investigators decided -at least for the purpose of this registry -to exclude TF TAVR (and other percutaneous TAVR) to reduce bias, given also the ambitious aim to provide a clear picture of short-, mid-, and long-term results of the different surgical options currently available for the treatment of SAVS. C: None.
3.The Registry is described, and in the second part of the protocol, the investigators describe aims. The investigators have not described any hypothesis, general or testable. A: According to previous comment, the second part has been completely deleted, and a single merged protocol with declared aim and hypothesis is now reported. Thus, a sample size calculation based on the main hypothesis has been reported in the text. C: In the Methods section, "Rationale of the study and aim", it has been specified: "…[OMISSIS]…The primary aim of the study is a 5-year comparison between SAVR and surgical TAVR: we hypothesize to report a 10% superiority in terms of all-cause mortality in favor of SAVR vs TAVR.". Accordingly, in the Methods section, "Statistical Analysis" paragraph, we have now added the sentence: "Given the PARTNER TRIAL 5-year all-cause mortality risk (67.8% after TAVR and 62.4% after SAVR) -accepting a type 1 error of 5% -the overall number of patients needed to achieve 80% power (1-beta) for a mortality odds of 1.1 (10% mortality difference) is 2866 patients (i.e. 1433 patient/group) (7). Therefore, the expected number of 8000 patients is far beyond the requested sample size of the primary objective of the registry, and further accounts for risk-adjustment methodologies and the expected 1.5% (historical data) of lost to follow-up." Finally, in the Ethics and Dissemination section:…[OMISSIS]….Several studies are planned at the moment: Primary study: 1) A 5-year study comparing all-cause mortality between SAVR and surgical TAVR. We expect to report a 10% superiority of SAVR vs. TAVR according to sample size calculation and literature data (7). This study will also report echocardiographic data, functional status, quality of life, incidence of cardiovascular mortality, reinterventions on the aortic valve, and incidence of structural valve deterioration between "all-comers" surgical TAVR and SAVR. The study is expected 6-years after the start of data collection and it is aimed at being presented in a major European cardiology journal…[OMISSIS]… 4.The authors have identified 30-day cardiovascular mortality as the primary outcome. I expected that 1 year, 2 year, or 5 year mortality would be the primary outcome. Please comment. A: We thank the reviewer for his valuable suggestion, that we take. Therefore 5-year all-cause mortality is now the primary endpoint. That also in light of the fact that the sample size calculation and power analysis -based on another comment from this reviewer -were made on literature data on 5-year all-cause mortality of SAVR and TAVR. C: Abstract (Methods and Analysis): "Primary outcome is 5-year all-cause mortality. Secondary outcomes aim at establishing "early" 30-day all-cause and cardiovascular mortality, as well as major morbidity, and "late" cardio-vascular mortality, major morbidity, structural and non-structural valve complications, quality of life and echocardiographic data." Early and late endpoints paragraph: "…[OMISSIS]…Primary outcome of the E-AVR registry: 5-year all-cause mortality …[OMISSIS]… Early secondary outcomes: all-cause mortality, cardiovascular mortality, stroke, …[OMISSIS]… Late secondary outcomes (collected starting from discharge to the end of the 10th year after the index procedure): cardiovascular mortality, all-cause mortality (from 1 to 4 years after surgery, then from 6 to 10 years), stroke, …[OMISSIS]…" 5.The authors have described the overall sample size, but not the sample size for different subgroups. The authors have not provided sample size calculations for any of the study aims. A: We have now reported the main hypothesis and aim of the registry, as well as the sample size calculation for that. Sample size calculations for subgroup analyses are waived given the exploratory nature of these sub-studies (clearly stated in SPIRIT checklist). C: In the Methods section, "Statistical Analysis" paragraph, we have now added the sentence: "Given the PARTNER TRIAL 5-year all-cause mortality risk (67.8% after TAVR and 62.4% after SAVR) -accepting a type 1 error of 5% -the overall number of patients needed to achieve 80% power (1-beta) for a mortality odds of 1.1 (10% mortality difference) is 2866 patients (i.e. 1433 patient/group) (7). Therefore, the expected number of 8000 patients is far beyond the requested sample size of the primary objective of the registry, and further accounts for risk-adjustment methodologies and the expected 1.5% (historical data) of lost to follow-up."
6.Is there a central core echo lab? Will the central core lab review preoperative and postoperative echos? A: Although a Central core lab will enhance the quality of the study, this achievement was impossible to reach during study planning. Therefore, we decided to maintain Institutional echo data. This concept was added as a Limitation to the text (although it should be considered that Echo-Lab of the involved Institutions are all ISO9001 and 3rd level certified by national -and sometimes Europeansocieties) C: "Strengths and Limitations of this study" paragraph: "…[OMISSIS]… Limitations include absence of a Central Core Laboratory for echocardiographic assessment….
[OMISSIS]…" Early and Late endpoints paragraph: "Echocardiographic data of prosthesis performance are defined according to the Valve Academic Research Consortium-2 definitions (36). Although absence of a Central Core Echocardiographic Lab is a limitation, all the echocardiographic data will come from 3rd level national and/or international certified Institutional Echo Labs. " 7.Are events centrally adjudicated? And can be blinded to some of the key procedural factors? A: Based on this comment, we have better specified now that data will be collected at single Institutions. As already reported however, data will undergo auditing from the Central Core Lab on a regular basis. Unfortunately, the study plan is "open", thus no blinding towards data was considered. Indeed, we have specified also that Central Core Lab will be blinded towards the Centre. We think that this might not be a major issue, given that data will be audited by an external Statistical Core Lab, who will perform the entire set of statistical analyses. C: Data Management and Monitoring paragraph "…Events and outcome variables will be adjudicated after agreement of two local E-AVR Investigators, and collected at local Institutions. In the event of controversy on outcome adjudication between the two local E-AVR Investigators, the outcome will be discussed and adjudicated after a final consult inside the E-AVR Steering Committee…." Early and Late endpoints paragraph: "Collection of data is under the responsibility of the Representing Member inside the Steering Committee from each of the participating centres. Data will be audited from the Central Core Laboratory on a regular basis, as reported previously." Data Collection paragraph: "Participating Centre: Each participating centre will be anonymized by identification with a capital letter. The correspondence between centres and capital letters will only be known by the PI of the study. The Central Core Laboratory analyzing the data will be blinded towards the surgical teams."
8.What will happen if there are new RCTs or new implantable devices in terms of this Registry? Will such patients be excluded from this Registry? Will they be included? Will the participating centres be disallowed from participating in other investigational protocols? This question also applies to new protocols for medical treatment of valvular heart disease patients. A: In case of new devices or new protocols of medical treatment, there is no preclusion to consider these "new devices/protocols" in the Registry, given that all the analyses will be propensity-scored or risk-adjusted. Therefore, there is already the plan to consider all the potential biases in future analyses, and to manage them accordingly with several statistical techniques. Obviously, patients eventually enrolled in future RCTs might be excluded from the Registry according to the potential strict RCT's rules. In this case, the number (and causes) of patients excluded from the registry will be highlighted in future publications. However, no Centre has planned at the moment to participate in any forthcoming RCT, and there is the agreement to try to avoid future participation in RCTs dealing with SAVS. C: In the interest of space, no specification on hypothetical future problems has been added to the text.
9.The Registry is an "all-comers" study. As I initially read through the protocol, I wondered whether that was necessary. As the field is changing quickly, it is probably worthwhile to recruit all patients. A: Based on other comments from this reviewer we have better detailed that the Registry is an "allcomers" study on the treatment of SAVS. However, given that the primary objective of the study -as for other comments -has been clearly identified and based on a SAVR vs surgical TAVR comparison, some restrictions seems to be necessary to avoid "uncorrectable bias": for these reasons we decided to collect ALL patients coming with a SAVS±coronary disease, but without need for concomitant surgical procedures (other than a surgical aortic valve replacement ± myocardial revascularization). For the same reasons aortic root diseases are not considered (they are a different disease, at least in our opinion), as well as pure aortic regurgitations. C: Based on several reviewer's comments we have added a "better-detailed" list of inclusion and exclusion criteria. In "Criteria for registry-enrolment" paragraph: "The following inclusion and exclusion criteria will be considered: Inclusion criteria Age >18 yy Isolated SAVS with or without concomitant aortic valve regurgitation Isolated prosthetic aortic dysfunction SAVS + coronary artery disease (CAD) Prosthetic aortic dysfunction + CAD Elective, urgent and emergent procedures Endocarditic aetiology Exclusion criteria Patients undergoing concomitant mitral valve surgery, or tricuspid valve surgery, or aortic surgery (i.e. composite aortic valve and ascending aorta replacement with o without circulatory arrest), or atrial fibrillation surgery, or any other associated cardiac surgical procedure (with the exception of CABG) Concomitant aortic root procedure (i.e. Bentall operation, David operation, homografts, autografts) SAVR with techniques of aortic annular enlargement Porcelain aorta Pure aortic valve regurgitation Percutaneous TAVR requiring surgical cut-down (i.e. failure to comply with a full percutaneous approach, thus configuring a "hybrid procedure") Patient refusal" The same specifications were added to the flowchart (Fig.1). 10. Page 5, Line 18: The authors say that 5 years will provide definite answers -I disagree. 5 years is OK for inoperable, intermediate risk, and maybe for elderly low risk, but not for an "all-comers" study. Information about valve durability will not apparent after only 5 years of F/U -which is a very important question for low risk SAVR (or TAVR) patients. Much longer F/U is recommended. A: We thank the reviewer for his valuable comment. We agree with this suggestion. Accordingly, what we have previously considered a "minimum follow-up of 5 years" has been clarified that it will be extended to a "maximum of 10-year follow-up" for each patient. C: Rationale of the study paragraph: "...[OMISSIS]… For the purpose of this study, patients will be consecutively enrolled for a 2-year period, and will be followed-up for a minimum of 5 years after the index surgical treatment. Maximum follow-up length will be 10-years after surgery." Criteria for registry enrolment paragraph: "Every patient will be followed up at 30 days, 6 months, 1 year, and yearly thereafter up to a minimum of 5 years after the index surgical procedure (Figure 2 ). Afterwards yearly follow-up will be closed at the completion of the 10th year from surgery for each patient." 11. Page 5, Line 34: Is it not possible to maintain the blinding of some of the analysis team? A: We appreciated and take the reviewer's suggestion. A Central Core Lab with no commitment will manage the entire set of data (by auditing and by performing all the future statistical analyses). However, there will be blinding against the surgical team because each institution will be identified in the Database with a Capital Letter. C: Data collection paragraph: "…Participating Centre: Each participating Centre will be anonymized by identification with a capital letter. The correspondence between Centres and capital letters will only be known by the PI of the study. The Central Core Laboratory analyzing the data will be therefore blinded towards the surgical teams." 12. Page 6, Line 25: The authors mention a "number" of sutureless aortic valves. Is that true? The authors should list them. I know of Intuity (Edwards) and Percevel (Sorin).
A: We agree with the reviewer's statement. We better explained this concept and rephrase the sentence C: "There are on the market two types of "sutureless" valves (i.e. Sorin Perceval and Edwards Intuity) at the moment -aimed at reducing some surgical drawbacks such as cross-clamp time and myocardial ischemia-reperfusion injury (13,15-20) -and it is possible that new "sutureless" valves will enter the market in the next future."
13.Are there multidisciplinary Heart Teams in every centre who help decide on the mode of treatment of all AS patients? A: In all Institutions the local Heart Team already works in allocating the patient to the best treatment option. Therefore, this concept has been better clarified in the text. C: In the Rationale of the study paragraph of the Methods and Analysis section is now reported: " Patient allocation to a specific surgical procedure will be based on the local Heart Team decision at each Institution, according to standard clinical practice and current guidelines [2] ." 14.Page 9, Line 10: Patients will be followed for 5 years -is that a minimum, mean or median of 5 years? A: according to a previous comment, we have now better specified that a minimum of 5-year follow-up will be considered. C: Rationale of the study paragraph: "...
[OMISSIS]… For the purpose of this study, patients will be consecutively enrolled for a 2-year period, and will be followed-up for a minimum of 5 years after the index surgical treatment. Maximum follow-up length will be 10-years after surgery." Criteria for registry enrolment paragraph: "Every patient will be followed up at 30 days, 6 months, 1 year, and yearly thereafter up to a minimum of 5 years after the index surgical procedure (Figure 2 ). Afterwards yearly follow-up will be closed at the completion of the 10th year from surgery for each patient." 15. Page 9, Lines 12-9: Are TF TAVR cases performed through a femoral cutdown eligible? Carotid access is becoming popular as an alternative access site -are these cases eligible? Are autografts or homografts eligible, or only mechanical prostheses and xenografts? Are patients with annular or aortic enlargement eligible? Are patients with composite replacement eligible? Are patients with ascending aortic replacement not requiring circ arrest eligible? Are patients having AFib ablations eligible? Preoperative Diagnosis: Is the Registry only for patients with aortic stenosis? For AS/AI? For pure AI? Do patients need to have a specific gradient, dimensionless index, or AVA? Are low flow, low gradient AS patients eligible? Are patients with acute endocarditis, or undergoing emergency operation for valve thrombosis eligible? A: We thank the reviewer for this important comment. Therefore we have better specified the inclusion and exclusion criteria. In particular, only emergent surgery, endocarditis and coexistence of aortic regurgitation are inclusion criteria. Similarly, any SAVS (i.e including low flow low gradient; paradoxical low flow low gradient; regardless of gradients, AVA or AVAi…) will be included. All the other preoperative conditions and surgical options reported by the reviewer are exclusion criteria from the registry. C: Rationale of the study and aim: "Therefore, the rationale of this European multicenter observational open registry is to prospectively collect data on baseline characteristics, treatment options, perioperative management and postoperative outcome of all patients consecutively undergoing surgical treatment of SAVS (regardless of gradients, AVA or AVAi)±CAD or aortic prosthetic dysfunction±CAD at 17 European university or non-university tertiary hospitals located in six European countries (France, Germany, Italy, Spain, Switzerland, and United Kingdom)." Paragraph "Criteria for registry enrolment" now reports: Inclusion criteria Age >18 yy Isolated SAVS with or without concomitant aortic valve regurgitation Isolated prosthetic aortic dysfunction SAVS + coronary artery disease (CAD) Prosthetic aortic dysfunction + CAD Elective, urgent and emergent procedures Endocarditic aetiology Exclusion criteria Patients undergoing concomitant mitral valve surgery, or tricuspid valve surgery, or aortic surgery (i.e. composite aortic valve and ascending aorta replacement with o without circulatory arrest), or atrial fibrillation surgery, or any other associated cardiac surgical procedure (with the exception of CABG) Concomitant aortic root procedure (i.e. Bentall operation, David operation, homografts, autografts) SAVR with techniques of aortic annular enlargement Porcelain aorta Pure aortic valve regurgitation Percutaneous TAVR requiring surgical cut-down (i.e. failure to comply with a full percutaneous approach, thus configuring a "hybrid procedure") Patient refusal Same specifications are now reported also in the flow-chart (Figure 1) 16. Follow-up: Is F/U local in person, local by telephone, or central? A: We thank for this comment. Follow up will be local in person, and follow-up outcomes further checked by linking with regional Social Security Death and Events Master files (in those nations where these files are available). Only if data are missed or absent, variables will be collected by direct phone contact with general practitioners, and in case of persistently missing-data by phone contact with patients and families. These specifications are added to the new version of the paper. C: Data Management and Monitoring paragraph: "…[OMISSIS]… Baseline characteristics, operative details and outcome data pertaining hospitalization will be prospectively collected from hospital registries. Variables and events occurring after the index hospital discharge will be collected from outpatient clinics at the individual Institutions, and linking with regional Social Security Death and Events Master files where available. In case of absent/missing data, variables and events will be collected by direct phone contact with general practitioners, and only if persistently missed by phone contact with patients and families." 17. Consent: It is frequently difficult to obtain consent for a research study prior to an emergency operation. Will patients who underwent emergency surgery without consent for participation in the Registry, be approached for consent after the surgery? A: We thank the reviewer for the question. Informed consent for emergent cases will be collected from the family before surgery, and from the patient after surgery, in light of the long-term follow-up foreseen for these patients. However, "postoperative" consent (in emergencies) will be waived in case of death or severe neurological damage precluding adequate informed consent. C: Informed consent paragraph: "…[OMISSIS]…In case of emergent surgery, informed consent will be collected from the patient's family (or legal representative) before surgery, as well as from patient after surgery (if unable to give it before intervention). This consent will be waived in case of death or severe neurological damage precluding adequate postoperative patient informed consent...[OMISSIS]…." 18.Page 10 Data Management and Monitoring: I am unsure of the meaning of the last sentence in the paragraph. A: We thank the reviewer for pointing out the "unclear" sentence. The sentence only (and "unclearly") stigmatizes that the entire set of future statistical analyses performed by the central statistical core-lab will be sent to all co-authors for "transparency" and clinical "interpretation" of data during the process of writing a scientific paper. C: The sentence is now: "The entire set of statistical analyses will be available to all E-AVR researchers for the interpretation of data."
19.Page 10 Statistical Methods: What and where is the Core laboratory? Who is the study statistician? The statistics section mentions a number of statistical tests, but does not provide text such as which test will be used for which comparison. A: Based on this comment we have detailed the Core Laboratory in the "Data Management and Monitoring" paragraph. The Core Laboratory is the "Unit for Clinical Research and Biostatistics, Verona University Hospital, Verona, Italy", whose Director is Ms G. Bisoffi, Biostatistician. However, her name is not added to the text as co-Author at the moment because the single biostatistician responsible for each analysis has not been already identified by Ms Bisoffi (however, a statement on her statistical support is added to the Acknowledgements). Furthermore, the previously unexplained statistical tests have been now clarified in the text of Statistical Methods paragraph C: In "Data Management and monitoring" the following sentence is now reported "Data will be collected into a dedicated datasheet with predefined variables.. [OMISSIS] ... Storage, analysis and auditing of data will be accomplished by an independent Central Core Laboratory (Unit for Clinical Research and Biostatistics, Verona University Hospital, Verona, Italy)." In "Statistical Methods" paragraph it is now reported "Univariate analysis will be performed using the Mann-Whitney U test and Student's t-test for continuous variables (pending the not-normal or normal distribution respectively), the Kruskall-Wallis test (independent multilevel ordinal variables), Wilcoxon test (for paired variables), Fisher exact test and Chi-square test (for dichotomous/nominal variables) and Kaplan-Meier test (for time-dependent dichotomous variables). Multivariable analyses will be performed using logistic regression method (for categorical dependent variable), classification tree analysis (for target variables with a discrete set of value), linear regression (for continuous dependent variable) and ordinal regression methods (for ordinal dependent variable), as well as Cox-proportional hazards method (to test the effects of covariates on time-dependent dichotomous variables)." 20.Page 11 Interim Analysis: Are there statistical penalties for the interim analyses? A: We thank the reviewer for the precious comment. The statistical method to correct for interim analysis p-values has been specified in the text and referenced C: Statistical analysis paragraph: "Interim analyses are planned at different time-points (see Ethics and Dissemination). Critical p-values of accomplished interim analyses will be corrected according to the Armitage-McPherson adjustment (36)." 21. Page 11 Early Secondary Outcomes: The authors mention, "device success, early safety, clinical efficacy, time-related valve safety". How are these outcomes defined? A: We have better specified the significance of these outcome, which are concordant with last VARC-2 definitions. C: Composite outcome subparagraph: "..[OMISSIS]….according to VARC-2 definitions (36), this includes: 1) device success (absence of procedural mortality with correct positioning of a single prosthesis and with intended performance of the prosthesis); 2) early safety at 30 days (composite endpoint of all-cause mortality, all strokes, life-threatening bleeding, acute kidney injury stage 2 or 3, coronary obstruction requiring intervention, major vascular complication or valve-related dysfunction requiring repeat procedure); 3) clinical efficacy after 30 days (composite endpoint of all-cause mortality, all strokes, hospitalization for valve-related symptoms or worsening congestive heart failure, NYHA class III or IV, valve related dysfunction); 4) time-related valve safety (composite endpoint of structural valve deterioration requiring repeat procedure, prosthetic valve endocarditis, thrombosis, thrombo-embolic events or valve-related VARC bleeding ). A: Based on a previous comment, this second part of the protocol has been completely deleted, and a single merged protocol with a SPIRIT checklist is now submitted. C: The sentence (and the entire second part of the protocol) were deleted. 29. Page 49: "Analysis of costs related to hospitalization of AS-patients treated with different surgical modalities (e.g. sutureless valves vs stented/stentless, sternotomy vs minimally-invasive, standard SAVR vs surgical TAVR, etc) and evaluations of cost/effectiveness". The authors do not describe much in terms of the acquisition of cost data. A: Based on a previous comment, this second part of the protocol has been completely deleted, and a single merged protocol with a SPIRIT checklist is now submitted. Cost-effective analysis is no more considered as a potential sub-study of the registry. C: The sentence (and the entire second part of the protocol) were deleted. This paper is the design of a study aiming at comparing in the real life outcomes of different surgical strategies for patients being referred in the participating centers for aortic valve replacement. This study comes in a timely manner. The question is highly relevant. The paper is well written, outcomes are clearly defined. The sample size in the context of a multicenter study is large and appropriate. My only question is how the authors are sure that all surgical strategies will be sufficiently represent, especially for propensity matching comparisons of outcome data between groups. A: We thank the reviewer for his overall appreciation of the study/registry. Based also on Editor's request and another reviewer's request a sample size calculation is added to the text. Furthermore, a primary objective (therefore a main outcome study) has been clearly identified, and all the sub-studies planned to date should be considered in their "exploratory" nature. Therefore sample size calculation was waived for these "sensitivity" sub-studies. However, as easily deductable from the sample size calculation, the expected number of enrolled patients (>8000) is far beyond the requested sample size of 2866 patients (to reach 80% power to detect a 10% difference in all-cause mortality at 5 years), and it accounts for risk-adjustment methodologies and the expected 1.5% of lost to follow-up (based on historical data). Coming back to the reviewer comment, we are sure to have all the surgical techniques sufficiently represented in the Registry, because most of the enrolled centres are high-volume centres and still have different options of surgical treatment of SAVS (transcatheter and surgical, via minimally invasive or full-sternotomy approaches, stented or stentless valves, etc.), which are differently used in their daily practice. We think therefore that merging data from these high-volume Centres will help to overcome the "local bias", and help to have a large number of patients treated with each technique, amenable to different statistical tools (e.g. risk-adjustments and propensity-scores) able to reach conclusive data. C: C: In the Methods section, "Rationale of the study and aim", it has been specified: "…[OMISSIS]…The primary objective of the study is a 5-year comparison between SAVR and surgical TAVR: we hypothesize to report a 10% superiority in terms of all-cause mortality in favor of SAVR vs TAVR.".
